With filings in major developed markets beginning to emerge for proposed biosimilars to denosumab, Fresenius Kabi is continuing to position itself for the opportunity, reporting that its FKS518 candidate referencing Prolia (denosumab) successfully met its primary and secondary objectives in a pharmacokinetic similarity clinical trial.
Kabi Makes Progress With Denosumab, Phase III Due To Complete
Sandoz Emerged Earlier This With US, EU Filings, US Lawsuit Followed
Fresenius Kabi has welcomed “another testimonial of our efforts to expand our biosimilar portfolio,” with an update for its FKS518 biosimilar denosumab candidate.
